Schering-Plough Takes The Long Road To Early Stage Hep C R&D

The firm is conducting a 24-week, Phase II study in non-responders to pegylated interferon and ribavirin.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet